Are Medical Stocks Lagging Alkermes (ALKS) This Year?

Here is how Alkermes (ALKS) and CASI Pharmaceuticals Inc. (CASI) have performed compared to their sector so far this year.

Zacks Investment Research • Jan 15, 2026

Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?

Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Jan 14, 2026

Best Value Stocks to Buy for Jan.14

GES, NESR and ALKS made it to the Zacks Rank #1 (Strong Buy) value stocks list on Jan.14, 2026.

Zacks Investment Research • Jan 14, 2026

Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 13, 2026

Alkermes: Avadel Deal And Vibrance-2 Unlock Upside

Alkermes is transforming into a fully integrated biopharma, leveraging Vibrance-2 results and the Avadel acquisition for competitive advantage in sleep medicine. ALKS's robust legacy portfolio funds rapid R&D expansion, with Lybalvi sales up 32% and strong gross-to-net dynamics supporting operational profitability. Alixorexton's Phase 2 success in both narcolepsy types and idiopathic hypersomnia, plus a clean safety profile, significantly de-risk the clinical pipeline.

Seeking Alpha • Jan 9, 2026

FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug

Alkermes wins FDA Breakthrough Therapy status for alixorexton in NT1 after Vibrance-1 data shows improvement in wakefulness.

Zacks Investment Research • Jan 7, 2026

Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and phase 2 clinical data, including positive results from Vibrance-1, a large (n=92) phase 2 study evaluating alixorexton in patients with NT1. Alixorexton is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in developm.

Business Wire • Jan 6, 2026

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc (Nasdaq: ALKS), a mid-cap growth.

Business Wire • Dec 30, 2025

Avadel Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avadel Pharmaceuticals plc - AVDL

NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PRNewsWire • Dec 12, 2025

Are Investors Undervaluing Alkermes (ALKS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Dec 8, 2025